C-Q4XZSensei Biotherapeutics
oncology, PAM pathway inhibition, oral multi-node therapy
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-Q4XZ
C-Q4XZC-Q4XZoncology, PAM pathway inhibition, oral multi-node therapy
0-100 chain-logic scale · 15 dimensions · scored on public evidence
The study is a Phase 1b/2, multi-center, open-label, dose escalation trial evaluating the safety and preliminary efficacy of sapanisertib and serabelisib (PIKTOR) with fulvestrant and/or other anticancer therapies in participants with HR+/HER2- advanced/metastatic breast cancer.
This is a Phase 2, multicenter, open-label, single-arm study to evaluate the efficacy and safety of sapanisertib and serabelisib (PIKTOR) with paclitaxel in participants with advanced or recurrent endometrial cancer.
Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of SNS-101, a novel anti VISTA IgG1 monoclonal antibody as monotherapy or in combination with cemiplimab in patients with advanced solid tumors.
This is a multicenter, randomized, open-label Phase 2 study of sapanisertib in biomarker-defined populations of sqNSCLC. Patients with NFE2L2 (the name for gene encoding the protein called NRF2)-mutated or wild-type sqNSCLC should have disease that has progressed on or after at least two prior systemic therapies for metastatic disease including platinum-doublet chemotherapy and a programmed cell death 1 ligand 1 (PD-L1) inhibitor. The study will evaluate sapanisertib monotherapy in patients with relapsed/refractory sqNSCLC as two separate groups: Group A: NFE2L2-mutated sqNSCLC and Group B: NFE2L2-WT sqNSCLC.
This is a single arm study evaluating the tolerability and markers of colorectal cancer with a specially designed medical food restricted in specific amino acids for the dietary management of subjects with metastatic colorectal cancer. Subjects will be receiving two FDA approved second line drug therapies, fluoropyrimidine and oxaliplatin ± bevacizumab (FOLFIRI + BEV) that are routinely prescribed in combination for metastatic colorectal cancer as part of their routine care.
This study will evaluate the feasibility of optimizing the safety and tolerability of serabelisib (an investigational PI3K inhibitor) when combined with an ISD and with or without nab-paclitaxel with a goal of reducing side effects and enhancing anticancer activity.
This is a single arm study evaluating the tolerability and markers of pancreatic cancer with a specially designed medical food restricted in specific amino acids for the dietary management of subjects with locally advanced and unresectable or metastatic pancreatic adenocarcinoma. Subjects who are eligible to receive two FDA approved first line drug therapies, gemcitabine and nab-paclitaxel (gem+nabP), routinely prescribed in combination for pancreatic cancer may be included in this study.
To evaluate safety, immunogenicity and anti-tumor responses of intradermally delivered SNS-301 in patients with ASPH+ high risk MDS and CMML.
To evaluate safety, immunogenicity and anti-tumor responses of intradermally delivered SNS-301 added to checkpoint inhibitor therapy in locally advanced unresectable or metastatic/recurrent squamous cell carcinoma of the head and neck (SCCHN) patients.
This is a Phase I, open-label, parallel design study of PAN-301-1 (SNS-301), a HAAH directed nanoparticle vaccine, given intradermally in cohorts of patients with biochemically relapsed prostate cancer, using a fixed dose escalation schema every 21 days.
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Kasra Ghanbari - Public launch today of our new Indie... Facebook Log In Kasra Ghanbari's Post Kasra Ghanbari January 30 · Shared with Public Public launch today of our new Indie Comics Creator Con show in Jacksonville done as a co-promotion with the great folks at First Coast Comic Con ! Exhibitor applications are now open at our www.IC3.art site and contact First Coast Comic Con to get one of the few remaining exhibitor booths with them. First Coast Comic Con January 30 · Shared with Public First Coast Comic Con and IC3 are thrilled to reveal our 2026 Featured Guest lineup! Both teams h
Jan 27-29, 90+ Exhibitors at PMWC 2027 Silicon Valley Chat with us , powered by LiveChat Skip to content Chats Contact Speakers Agenda Tickets Menu FULL MENU FULL MENU Register here Rates by JUL. 2 Register here PMWC, Jan 25-27, 2023 PMWC - Silicon valley, ca January 27-29, 2027 Past Event PMWC, Feb 5-7, 2025 PMWC - Silicon valley, ca January 27-29, 2027 Attend Program Schedule Sessions Honorees Speakers Company Competition Showcases Travel Venue Sightseeing Reduced Rates Hotel Flights Exhibits + Map Login / My Account Participate REGISTER TO EXHIBIT Prospectus Attendee Breakdown Apply to spea … ogin / My Account Participate Register to Exhibit Prospectus Attendee Breakdown Apply to speak Sponsorship Inquiry GET UPDATES ABOUT Mission Testimonial Past Conferences Past Honorees Past Speakers FAQ CONTACT US Menu agenda speakers exhibits Contact us agenda speakers exhibits Contact us BUY TICKETS SAVE $1351 BY JUL. 2 Menu Item #1 Item #1 PMWC - Silicon valley, ca Jan. 27-29, 2027 Pittsburgh, pa sep. 23-24 PMWC - Silicon valley, ca Jan. 27-29, 2027 Register Here Rates by J … tend Program Speakers Travel Exhibits + Map Main Program View your save program Award Reception Speaker gallery Select part speakers Exhibit gallery Part conferences Participate Register to Exhibit Apply to speak Sponsorship Inquiry ABOUT Login / My Account CONTACT US Get Updates Pittsburgh, pa sep. 23-24 Register Here Rates by Attend Program Travel Reduced Rates Exhibits + Map Main Program View your save program Award Reception Paticipate Register to Exibit Apply to speak Sp … nomix Labs Alphaexpeditions Alpine Alquest Therapeutics ALS Emergency Treatment Fund Alta Bates Summit Comprehensive Cancer Center Alta Devices AltaQ Altered Egos Comics AltheaDx Althia Altiora Altis Biosystems, LLC Altoida Inc Altos Labs AltruBio Altum Medical Alum Alumot – sprint Aluna Health Alva10 Alveo Technologies Alverno Laboratories AlwaysRx Alykomed Global Solutions LLC Alykomedglobal Alzheimer’s X Alzheon AMA Ama-Assn Amaro Therapeutics Amazon Amber Health Amb … Y Ancestry Anderson Cancer Center Andreessen Horowitz Andrew Andy Strouse Angel Fund Angel Investor ANGLE Biosciences ANGLE Europe Ltd. ANGLE, plc Angleplc Angstrom Bio Angular Medicine Anima AnjaGen Consulting Anl Annai Systems, Inc Annexon Biosciences Annexon Inc Annexonbio Anocca Ansun Biopharma Antenna Anthem Anthony Pastena, M.D. ,P.C Anthos
SNSE Stock Surges To 21-Month High – Everything To Know About Its Faeth Therapeutics Acquisition Use App Trending News Earnings All DIA 0.29% SPY 0.72% QQQ 1.38% Trending RAVE 15.68% CCXI 11.41% OTLY 2.51% EMAT 2.77% NEAR 5.27% JBL 4.28% MA 2.07% BLK 0.74% FCX 0.56% BMY 3.85% RAVE 15.68% CCXI 11.41% OTLY 2.51% EMAT 2.77% NEAR 5.27% JBL 4.28% MA 2.07% BLK 0.74% FCX 0.56% BMY 3.85% Home News Markets Equity SNSE Stock Surges To 21-Month High – Everything To Know About Its Faeth Therapeutics Acquisition Advertisement | Remove ads. SNSE Stock Surges To 21-Month High – Everything To Know About Its F … ually love to read. It's value-packed, data-driven, and seasoned with wit. Submit Read about our editorial guidelines and ethics policy Retail Equities US Latest News Cathie Wood's Ark Invest Resumes Buying Crypto Stocks After A Week-Long Pause Anushka Basu · 1h ago After Bitcoin's Collapse, The Average IBIT Investor Has Swung From A 30% Gain To A 40% Loss, Analyst Says Anushka Basu · 2h ago BlackRock-Linked Securitize Eyes NYSE Debut With $400 Million Haul As
Faeth Therapeutics, News (NAQ:FTH) Jun 2026 | Stockopedia Home StockRanks™ Platform Insights Research & Discuss Editorial & Community Learn & Improve Webinars & Masterclasses Stockopedia Academy Reviews Pricing Get started Log in Sectors Healthcare Biotechnology & Medical Research Faeth Therapeutics, FTH — Faeth Therapeutics, Share News 0.00 0.00% Last trade - 00:00 Healthcare Speculative Mid Cap Momentum Trap Market Cap $589.56m Enterprise Value $386.79m Revenue Quality Value Momentum Stock Rank ™ StockReport™ Accounts Balance sheet Income statement Cashflow statement Divi
%PDF-1.6 %���� 524 0 obj > endobj 544 0 obj >/Filter/FlateDecode/ID[ ]/Index[524 34]/Info 523 0 R/Length 102/Prev 3997374/Root 525 0 R/Size 558/Type/XRef/W[1 3 1]>>stream h�bbd```b``� "C����LN�@$�R0;Ln�\�`rX�D�-�c"%�Iƥ�`c)� $�O=�����4$��������+@��^K endstream endobj startxref 0 %%EOF 557 0 obj >stream h��TmHSQ~����5��CR����H!�Bm��j�ѰZ�>`�1o#R���v�"i����b�y��H�QD ��\�Ȣ(��}�{�Ԥ~��{x������=��9T�j@݀\�~�4��F��]��ju ��[�ƫ��ƻ�� [����G�����sk�w��?w���7�� ��p�����7� �\ a� -�!� � �! 5z�NpO� �K�>$�] 8{�k�y�)�%N%�&t���0TB��=��q�K^#��{��a� ���;NK\ �{!A��4A … 04-09T13:52:39-04:00 2025-04-09T13:51:27-04:00 Acrobat Distiller 25.0 (Windows) application/pdf SNSE-10K-2024-1231 (2).pdf cflood uuid:647adf49-ea51-49ad-8e9d-bf1ab50ca1dd uuid:d90503b5-abca-4d53-b885-96a8e92da327 endstream endobj 373 0 obj >stream hޜ��j 1 ��W��%Y�!� { !��C�K�% Mz��׳�.��vN? ��� 7�?�o�� �Ka������4��J��Nr&w��븀8����tp�ŒN(��*#��{�#o���5Xs�ʻ��9jYEK�罞V�:��� ��#���5Ӛ����΅t��);X�;*�M�NjJV���]up߃Wp6Z+x�x�7���� ��w�>����|�� ��� 2q�x��8>v��Ͽ8'�l������
Sensei Biotherapeutics names Anand Parikh CEO; Brian Stephenson appointed CFO — TradingView News Search Products Community Markets Brokers More EN Get started News / TradingView / Sensei Biotherapeutics names Anand Parikh CEO; Brian Stephenson appointed CFO Sensei Biotherapeutics names Anand Parikh CEO; Brian Stephenson appointed CFO 1 min read Sensei Biotherapeutics appointed Anand Parikh as President and Chief Executive Officer and named Brian Stephenson as Chief Financial Officer, both effective June 13, 2026. Individual Anand Parikh Brian Stephenson Josiah Craver Christopher W. Gerry Steph
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
Sensei Biotherapeutics adds two board directors | SNSE 8-K Filing --> STOCK TITAN Login Sign up Login Sign up 0 HOME --> NEWS FEED Stock News Live Stock News Today Trending News AI news FDA Approvals Clinical Trials Crypto News Merger & Acquisitions Earnings Offerings IPO News Stock Splits Top News - Gainers Top News - Losers SEC FILINGS SEC Filings Live SEC Filings Today Form 4 - Insider Trading 8-K - Material Events 10-K - Annual Reports 10-Q - Quarterly Reports DEF 14A - Proxy Statements S-1 - IPO Registration S-3 - Shelf Registration STOCKS All Stock Themes AI Stocks Crypto Stocks Oil & Ga … and equity components for outside directors. What indemnification arrangements apply to the new Sensei Biotherapeutics (SNSE) directors? Both Christopher W. Gerry and Phillip B. Donenberg will enter into Sensei Biotherapeutics’ standard form of indemnification agreement. A copy of this agreement was previously filed as an exhibit to the company’s Form 10-K for the year ended December 31, 2025, providing customary protection for directors. Filing Exhibits & Attachments 3 docu
8-K false 0001829802 --12-31 0001829802 2026-02-17 2026-02-17     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 8-K     CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 17, 2026     Sensei Biotherapeutics, Inc. (Exact name of registrant as specified in its charter)       Delaware   001-39980   83-1863385 (State or other jurisdiction of incorporation)   (Commission File Number)   (IRS Employe … defined below), the Company has agreed to hold a stockholders’ meeting to submit the following matters to its stockholders for their consideration (i) the approval, in accordance with certain of the rules of the Nasdaq Stock Market, LLC (“ Nasdaq ”) of the conversion of the Series B Preferred Stock into shares of Common Stock (the “ Conversion Proposal ”), (ii) the approval of a “change of control” under Nasdaq Listing Rules 5110 … 221; under Nasdaq Listing Rules 5110 and 5635(b) (the “ Change in Control Proposal ”), (iii) amendment of the Company’s certificate of incorporation to authorize an increase of up to 300,000,000 shares of Common Stock (the “ Charter Amendment Proposal ” and, together with the Conversion Proposal and the Change in Control Proposal, the “ Company Stockholder Matters ”), (iv) to the extent deemed necessary or advisable by the Company or … ve February 17, 2026, the Company granted Mr. Parikh a sign-on equity award consisting of an option (the “ Parikh Option ”) to purchase 1,239,305 shares of Common Stock at a per-share exercise price equal to the fair market value of a share of Common Stock on the date of grant. The Parikh Option is eligible to vest, on a schedule whereby 25% of the shares of Common Stock subject to the Parikh Option will vest on the first anniversary of the date of grant … #8217;s 2021 Equity Incentive Plan, and pursuant to the terms of the applicable award agreement. Mr. Parikh has no family relationships with any of the executive officers or directors of the Company. Except as otherwise described in the Merger Agreement, there are no arrangements or understandings between Mr. Parikh and any other person
Sensei Biotherapeutics Acquires Faeth; Secures $200 Million PIPE to Fund Growth — TradingView News Search Products Community Markets Brokers More EN Get started News / TradingView / Sensei Biotherapeutics Acquires Faeth; Secures $200 Million PIPE to Fund Growth Sensei Biotherapeutics Acquires Faeth; Secures $200 Million PIPE to Fund Growth 1 min read Sensei Biotherapeutics completed a tax-efficient acquisition of Faeth through a two-step merger, issuing 10,602.388 shares of Series B Preferred (convertible into 10,602,388 common shares). Assuming conversion, former Faeth and HoldCo holders woul … a $200 million PIPE of Series B Preferred expected to close on Feb 20, 2026, to fund clinical milestones. To support execution, the company entered stockholder support and 180-day lock-up agreements and granted PIPE investors registration rights for resale. Agreement 1: Sensei Biotherapeutics Acquires Faeth; Issues Series B Preferred, Former Holders to Own 89% Pre-PIPE Agreement type : Agreement and Plan of Merger Counterparty : Faeth Holdings Therapeutics and Faeth Therapeut … t 2: Sensei Biotherapeutics Secures $200 Million PIPE via Series B Preferred to Fund Combined Company Agreement type : Securities Purchase Agreement for PIPE financing Counterparty : Investors Signed / Effective : Feb 17 2026 / Feb 20 2026 Reason : Fund combined company through key clinical milestones Agreement 3: Sensei Biotherapeutics Grants PIPE Investors Resale Rights Following $200 Million Financing Agreement type : Registration Rights Agreement Counterparty : Investors
Lucid Capital Markets advises Sensei Bio on Faeth Therapeutics acquisition | David Strupp posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join o
Remote Jobs at Faeth Therapeutics, Inc. - Virtual Vocations Jobs How It Works Companies Career Center Blog Sign in Post a Job Remote Jobs Sign In More Explore Remote Jobs How it Works Companies Career Center Blog Sign in Post a Job FAQ Remote Jobs at Faeth Therapeutics, Inc. About the Company Faeth Therapeutics, Inc., founded in 2019 and headquartered in Austin, Texas, operates in the research industry. The company focuses on innovative cancer treatments by leveraging metabolism to combat the disease. Faeth employs a data-driven approach to match tumor genotypes with treatment regimens, aiming
%PDF-1.4 1 0 obj > endobj 3 0 obj > endobj 4 0 obj [/Pattern /DeviceRGB] endobj 6 0 obj > stream ����JFIFHH��C ��C ��d�"�� ���}!1AQa"q2���#B��R��$3br� %&'()*456789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz��������������������������������������������������������������������������� ���w!1AQaq"2�B���� #3R�br� $4�%�&'()*56789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz�������������������������������������������������������������������������� … je7y:T�'��۶��X��7̣N�m��0� Q�⧈���Jo܊��K$#�Ȇ9(�����y���G�O�.ơ�h�\^�$x�;�rFp?\��.�u��lLTq8z8��u��H��v}WMtd���i�Tur�� �U��\� \�c�����h�d�K6� �Oe��z�����Cì�[�6�hB �[�K `��ǷLv5�-�LJ�8T���r�R��,5= Ӻ�G����� �&x�_�5���K��y�!� ,���m,�Zy��/C�48�I��A a^À?�z{h.�hn �/�E��xSH���ػ�q%�$��w$u�ǶLj� �'� W��݆�0ç��O�W]Ec ^ 8 �f��?j���^��/�[U��� :��=�Z�Y�e*'� ��9 +e\C ���q��� `�[ %�qX�N #������ ���B�SP���?�?ֽ���@O�\��⚇�|I����B�X��O���B�ur��z���}�/��_�Ə�Ǭ … �����(�+��kW�]O�PA=�֒$ko�\�me � pǔEUR�1�V(-�[�F.-� ����� �[��w�] �5+h.W���RfP `�����?��|y��?�ZÏ�K|�4�&�{D`_!rI$�pq�W��X�gO�����Z������P'���`����9�ʏ�6G��I����t������q���#�����}=({�mNmy+'�7ʚ]mg}6�>V��|S�t�x� ��e�ʓ�i%w};�?1?ஞ���'��Ja��|)�OZ�jk>u�Z�5��K�ϖTe`'���F ����T��� �� \�&����ֶv�j�]�h�p��˕���ݐwzq��B���=x�w�o�#�I�Ƴ���q �����4��KC6@烕�8��/���l����y�|7���xKW�i�c��n��c��z�����@����q��ĩS�$� �NI�K)/�}u ���-��q9b����:հ�\i�ʹ�$����?�� �O�Oi�1�k�7�u� … Q@w��F}Q��*Q��fc��$�4Q@Q@ �G�����9O�7] �}v�Ѧr�����$�x�O��E>Ǹ� ԛ�Gݽ�A�RfP?@���3 ��7�I$f ��斊(��(��(��(��(��(��(�� �_#��C?�ƾ!�[�Aj�� ��U�?�3�Lk� տ��q���8�h���o�Ɍ�#�����B� A����&���ς?��k_d/A� ʔv^�� n�_�-QLAEPEPEPEPEP|Ôv����k~c�֍�}>�{�O=�Ɩ�O�����?ޑ��'���Q@w���Q��������I$��ط�z(��(��#�pi���u���)h��J(�����w1�ʒ����M���zI+0Ǧ �KE �QE!�UfF�� 0�h�t:_�a;���h����Y4��V/��KEQEQEQEQEQEQEv��@�;��[R��Y��� �%{��������RW�ş�� ������1���M~_ … >�� ua�' c=������#�= ���Q�����b�o�O����Bo�6#L�g��1�2�BF�Lt��w��ir��n�-�rFP�9�������_�������_������g��(��!��;�w�;Z]G( �FÞ >���k�}�W��� ��E���B:�5N�OҺp�������(�^ߨQC�����(��-���{�H�b��(��(��@I �R�EQM���~T������S �� ��W�|P��m��B�֯"���9$�E�#�� ��#K F�z��J.s��F;��ۗ����C���bq5aJ�(�z��e������R����h����k�ğ�U��Z�Ι,�A+�IB>���
Faeth Therapeutics Appoints Debbie Chirnomas, M.D., M.P.H., as Chief Medical Officer, Park Square Executive Search Client Login Username Password Login Who We Are Why Us Where We Excel Education & Not-for-Profit Life Sciences & Healthcare Technology News Education & Not-for-Profit Life Sciences & Healthcare Technology Insights Education & Not-for-Profit Life Sciences & Healthcare Technology Contact Us Client Login Username Password Login Who We Are Why Us Where We Excel Education & Not-for-Profit Life Sciences & Healthcare Technology News Education &
Exhibitor Profile - PMWC Precision Medicine World Conference Chat with us , powered by LiveChat Skip to content Chats Contact Speakers Agenda Tickets Menu FULL MENU FULL MENU Register here Rates by JUL. 2 Register here PMWC, Jan 25-27, 2023 PMWC - Silicon valley, ca January 27-29, 2027 Past Event PMWC, Feb 5-7, 2025 PMWC - Silicon valley, ca January 27-29, 2027 Attend Program Schedule Sessions Honorees Speakers Company Competition Showcases Travel Venue Sightseeing Reduced Rates Hotel Flights Exhibits + Map Login / My Account Participate REGISTER TO EXHIBIT Prospectus Attendee Breakdown Apply … ogin / My Account Participate Register to Exhibit Prospectus Attendee Breakdown Apply to speak Sponsorship Inquiry GET UPDATES ABOUT Mission Testimonial Past Conferences Past Honorees Past Speakers FAQ CONTACT US Menu agenda speakers exhibits Contact us agenda speakers exhibits Contact us BUY TICKETS SAVE $1351 BY JUL. 2 Menu Item #1 Item #1 PMWC - Silicon valley, ca Jan. 27-29, 2027 Pittsburgh, pa sep. 23-24 PMWC - Silicon valley, ca Jan. 27-29, 2027 Register Here Rates by J … tend Program Speakers Travel Exhibits + Map Main Program View your save program Award Reception Speaker gallery Select part speakers Exhibit gallery Part conferences Participate Register to Exhibit Apply to speak Sponsorship Inquiry ABOUT Login / My Account CONTACT US Get Updates Pittsburgh, pa sep. 23-24 Register Here Rates by Attend Program Travel Reduced Rates Exhibits + Map Main Program View your save program Award Reception Paticipate Register to Exibit Apply to speak Sp … nomix Labs Alphaexpeditions Alpine Alquest Therapeutics ALS Emergency Treatment Fund Alta Bates Summit Comprehensive Cancer Center Alta Devices AltaQ Altered Egos Comics AltheaDx Althia Altiora Altis Biosystems, LLC Altoida Inc Altos Labs AltruBio Altum Medical Alum Alumot – sprint Aluna Health Alva10 Alveo Technologies Alverno Laboratories AlwaysRx Alykomed Global Solutions LLC Alykomedglobal Alzheimer’s X Alzheon AMA Ama-Assn Amaro Therapeutics Amazon Amber Health Amb … Y Ancestry Anderson Cancer Center Andreessen Horowitz Andrew Andy Strouse Angel Fund Angel Investor ANGLE Biosciences ANGLE Europe Ltd. ANGLE, plc Angleplc Angstrom Bio Angular Medicine Anima AnjaGen Consulting Anl Annai Systems, Inc Annexon Biosciences Annexon Inc Annexonbio Anocca Ansun Biopharma Antenna Anthem Anthony Pastena, M.D. ,P.C Anthos
Faeth Therapeutics Announces National Academy of Medicine Recognition for Co-founder Dr. Siddhartha Mukherjee - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Lone Star Bio Faeth Therapeutics Announces National Academy of Medicine Recognition for Co-founder Dr. Siddhartha Mukherjee October 13, 2023 | 2 min read Twitter LinkedIn Facebook Email Print Faeth Therapeutics proudly announces the induction of its co-founder, Dr. Siddhartha Mukherjee, Assistant Professor at Columbia, … co-founder, Dr. Siddhartha Mukherjee, Assistant Professor at Columbia, Pulitzer Prize Winner, and one of Time 100’s Most Influential People, into the esteemed National Academy of Medicine. AUSTIN, Texas--( BUSINESS WIRE )-- Faeth Therapeutics , a leader in metabolic oncology research and treatment innovation, proudly announces the induction of its co-founder, Dr. Siddhartha Mukherjee, Assistant Professor at Columbia, Pulitzer Prize Winner, and one of Time 100's Most Influenti … -resident stem cells. His book, “The Emperor of All Maladies,” won the Pulitzer Prize and was nominated by Time as among the century’s 100 most influential books, introducing millions to modern cancer research. This recognition accentuates the collective dedication and caliber of Faeth's team and the company's commitment to advancing the realm of cancer care. With Dr. Mukherjee's recent induction into the National Academy of Medicine, he joins fellow Faeth co-founders who hav … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
CORRECTING and REPLACING Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA M … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases CORRECTING and REPLACING Faeth Therapeutics’ $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer October 28, 2025 | 5 min read Twitter LinkedIn Facebook Email Print New $25 million raise advances multi-node PI3K program; randomized phase 2 trial with Gynecolog … Ventures and Cantos, plus new investors B Group Capital, Avicella and THO Seed Fund. Clinical data from sapanisertib in combination with paclitaxel, one component of the PIKTOR regimen, have been selected for a late-breaking oral presentation at the ESMO 2025 Congress. Faeth's phase 1b study of serabelisib + sapanisertib ("PIKTOR") with paclitaxel demonstrated an 80% overall response rate in endometrial cancer patients, with a median progression-free survival of 11 months ve … , Future Ventures, Digitalis Ventures, KdT Ventures, Cantos, Avicella, THO Seed Fund, and B Group Capital. For more information, visit faeththerapeutics.com . Contacts Media Contact Patrick Schmidt [email protected] Investor Contact [email protected] Twitter LinkedIn Facebook Email Print Texas Funding Phase 2 Cancer LATEST Duchenne muscular dystrophy Capricor thrown for another loop as FDA sets adcomm for DMD cardiomyopathy therapy June 26, … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Faeth Therapeutics Announces Late-Breaking Presentation of Positive Phase 2 Data in Ovarian Cancer at ESMO 2025 - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Tren … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Faeth Therapeutics Announces Late-Breaking Presentation of Positive Phase 2 Data in Ovarian Cancer at ESMO 2025 September 25, 2025 | 1 min read Twitter LinkedIn Facebook Email Print Imperial College London researcher-led trial demonstrated sapanisertib, also part of Faeth’s lead multi-node PIKTOR program, … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
EX-99.2 9 d112826dex992.htm EX-99.2 EX-99.2 Exhibit 99.2 –– Transaction & Company Overview CONFIDENTIAL 1 –– Disclaimers The information in this Presentation has been prepared by Sensei Biotherapeutics, Inc. ( Sensei ) and Faeth Holdings Therapeutics, Inc. ( Faeth and, together with Sensei and each of Sensei's subsidiaries, the combined company ) and contains information pertaining to the business and operations of the combined company. The information contained in this Presentation: (a) is provided as at the date hereof, is subject to change without notice, and is … ; Phase 2 in endometrial cancer reads out EOY 2026 ● Raise is expected to fund the combined company’s product candidates through key clinical readouts, including a Phase 2 trial in second-line advanced endometrial cancer through topline data and initiation of a Phase 1b trial in first- and second-line HR+/HER2- advanced breast cancer, with remaining proceeds for general corporate purposes and completion of Sensei's ongoing Phase 1/2 trial of solnerstotug. CO … Greg Hannon, PhD Dana Farber Cancer Institute, Asst. Prof., Columbia, Pulitzer Prize CSO & Co-Founder Group Leader, Crick Institute, Chair of Cancer Biology & Genetics at Director of CRUK Cambridge Harvard. Founder: Agios Winner, Time 100 Most Influential Honorary Professor of Cancer Biology & Former Chief Scientist of CRUK, Memorial Sloan Kettering, Institute (NASDAQ), People, Founder: Vor (NASDAQ) Metabolism, University of Glasgow Director, Bristol Myers … r all oncology indications CONFIDENTIAL 31 –– Financing expected to fund PIKTOR program through key anticipated catalysts 2026 2027 2028 Before EOY: Enrollment PIK-201 Last patient dosed + 6 complete, topline data Ph 2 Endo months data readout Interim safety data from dose escalation PIK-101 1H: Trial initiation, Ph1b Interim efficacy data from Expansion data Ph1b Breast dose escalation dose escalation Expansion cohorts initiated Potential FDA interaction DIC
5th Annual Cedars-Sinai Gastrointestinal Tumor Conference: Bringing the Future of Cancer Care to our Patients Today - Cedars-Sinai - Continuing Education (CE) Radiation Oncology</Profession><Profession>Radiology</Profession><Profession>Endocrinology &amp; Metabolism</Profession><Profession>Gastroenterology</Profession><Profession>Internal Medicine</Profession><Profession>Nuclear Medicine</Profession><Profession>Oncology</Profession><Profession>Pathology &amp; Laboratory Medicine</Profession><Profession>Family / General Medicine</Profes … Your Password ?" link. Forgot Your Password? Enter your Email address and click submit to have a login reset link sent to you. Back to Login {1} ##LOC[OK]## {1} ##LOC[OK]## ##LOC[Cancel]## {1} ##LOC[OK]## ##LOC[Cancel]## Create an Account: (All fields are required) Email: First Name: Last Name: Password: Password: Password Requirements Must be between 8 and 16 characters in length Must Contain at least 1 upper case character Must Contain at least 1 lower case character Must c … cation (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. How do you get the MOC Points? Before earning any MOC points, you must: Log into your account in the CME Portal (https://cedars.cloud-cme.com/) Update your profile with your board diplomate number and date of birth. Points will not be awarded retrospectively. Credits AMA PRA Category 1 Cre … 00 Includes: (1) 6ft Table Top, includes 2 chairs Number of Exhibitor Badges: 2 Deadline for order commitment is 3/14/2024 12:00:00 AM. Exhibitor Package - Virtual Company Profile Card Price: $1950.00 Includes: Posting on Meeting Sponsor Page Number of Exhibitor Badges: 0 Deadline for order commitment is 3/14/2024 12:00:00 AM. GI Tumor-Exhibitors by Cedars-Sinai CME CE Disclosure Form | CE Application | Privacy | Cedars-Sinai CME Homepa
Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer | Alec A. LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continu … Ventures and Cantos, plus new investors B Capital Group, Avicella and THO Seed Fund. https://lnkd.in/eJpbr8dg Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer businesswire.com 19 3 Comments Like Comment Share Copy LinkedIn Facebook X Cass Almendral 8mo Report this comment Congrats to Faeth Therapeutics and CEO Anand Parikh on this big $25M funding win—huge kudos to Alec for spotlighting them early! They're
Facebook Logged in on your phone? Scan with your phone's camera and confirm the codes match. DBV-UBG-UYNA Log into Facebook Email or mobile number Password Log in Forgot password? Create new account English (US) فارسی العربية Türkçe Deutsch Français (France) Polski More languages… Sign Up Log In Messenger Facebook Lite Video Meta Pay Meta Store Meta Quest Ray-Ban Meta Meta AI Instagram Threads Privacy Policy Privacy Center About Create ad Create Page Developers Careers Cookies Ad choices Terms Help Contact Uploading & Non-Users Meta © 2026
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
solnerstotug (SNS-101) / Sensei Biotherapeutics solnerstotug (SNS-101) / Sensei Biotherapeutics - LARVOL DELTA Home Next Prev 1 to 25 Of 67 Go to page 1 2 3 February 18, 2026 Concurrent with the acquisition, Sensei entered into a definitive agreement for the sale of Series B non-voting convertible preferred stock in a private placement financing, which is expected to result in gross proceeds to Sensei of approximately $200 million before deducting placement agent and other offering expenses. (Yahoo Finance) - "Sensei expects to use the proceeds primarily to advance PIKTOR through key clinical mi
While many leverage precision medicine, Faeth is banking on precision nutrition to tackle cancer | PharmaVoice Skip to main content CONTINUE TO SITE ➞ Don't miss the most important voices in pharma Let PharmaVoice's free newsletter keep you informed on what industry leaders are saying, straight from your inbox. By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy . You can unsubscribe at anytime. Informa TechTarget | BioPharma Dive Xtelligent Pharma Life Sciences Explore our brands An Informa TechTarget Publication Voices Q&A Profiles Biotech Spotlight Firs … than a decade of preclinical research from three of its co-founders — Pulitzer Prize winner Siddhartha Mukherjee, cancer metabolism pioneer Lewis Cantley and Cancer Research U.K.'s former chief scientist Karen Vousden — whose separate streams of research led them to the conclusion that “precision nutrition was an untapped treatment modality in the fight against cancer.” Together, they founded Faeth in 2019 with a goal to integrate precision nutrition into cancer care, and sh
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Sensei Biotherapeutics to Participate in the 32nd Annual Oppenheimer Healthcare Conference - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Ther … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Genetown Sensei Biotherapeutics to Participate in the 32nd Annual Oppenheimer Healthcare Conference March 3, 2022 | 1 min read Twitter LinkedIn Facebook Email Print Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, t … bsp; 2 min read · Tristan Manalac Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst China BIO 2026: US needs to dodge China’s ‘inescapable dependencies’ to protect biotech June 24, 2026 · 2 min read · Annalee Armstrong BioSpace at BIO to find out" href="https://www.biospace.com/drug-development/can-adcs-be-kin … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
JavaScript is disabled In order to continue, we need to verify that you're not a robot. This requires JavaScript. Enable JavaScript and then reload the page.
Science & Pipeline — Faeth Therapeutics About Science & Pipeline Patients Careers Investors Multi-node inhibition: Multi-node inhibition: overcoming the complexity overcoming the complexity of a major cancer pathway. of a major cancer pathway. PIKTOR The Challenge Clinical Results Pipeline Publications Single node inhibitors of the PAM pathway are approved for the treatment of certain cancers, but their class toxicities have constrained adoption. PIKTOR takes a different approach: by targeting multiple nodes simultaneously, each component is designed to be administered at substantially
Faeth Therapeutics: Combining therapies and diet to fight cancer | Oliver Maddocks posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign … RAS inhibitor antibody conjugates In the last 14 days, #WIPO published a patent application (WO2025212580) on novel antibody–drug conjugates ( #ADC ) that enable targeted delivery of #KRAS inhibitors for the treatment of cancers driven by mutant RAS oncogenes, particularly KRAS(G12D) and KRAS(G12V). 💡 RAS proteins are small GTPases that function as molecular switches controlling cell growth and differentiation. Mutations at key residues, particularly glycine 12, glycine 13,
Faeth Therapeutics Is Looking For Participants For Their Pancreatic Cancer Clinical Trial (203) 714-6052 CONTACT US Events Patients & Families Patient financial aid Blanket of hope Nutrition Assistance Program Informational Resources Cancer Risk Assessment Ways to give Get Active Volunteer Sponsorships Shop Donate Community Events About About Us Ways we help Financials And Annual Reports Research Committee Contact us News & stories Donate ALL STORIES NEWS AND STORIES Faeth Therapeutics Is Looking For Participants For Their Pancreatic Cancer Clinical Trial April 14, 2023 Faeth Therape
Science & Pipeline — Faeth Therapeutics About Science & Pipeline Patients Careers Investors Multi-node inhibition: Multi-node inhibition: overcoming the complexity overcoming the complexity of a major cancer pathway. of a major cancer pathway. PIKTOR The Challenge Clinical Results Pipeline Publications Single node inhibitors of the PAM pathway are approved for the treatment of certain cancers, but their class toxicities have constrained adoption. PIKTOR takes a different approach: by targeting multiple nodes simultaneously, each component is designed to be administered at substantially
JavaScript is disabled In order to continue, we need to verify that you're not a robot. This requires JavaScript. Enable JavaScript and then reload the page.
Sensei Bio stock skyrockets on acquisition and $200m financing Skip to content Drug and Device World Home News Pharma News Medical Device News Obesity News Sustainability Latest in Sustainability Sustainability News Company Progress Report and Analysis Expert Interviews AI & Tech Latest in AI and Technology AI and Technology News Expert Interviews Features Latest Features In Conversation With Exclusive Analysis Wellness & Lifestyle Members Only Become A Member Login Manage Membership FAQs Contact Us About the Author Contact Us Advertise Search Deals , News , Oncology , Pharma News Sens
Science & Pipeline — Faeth Therapeutics About Science & Pipeline Patients Careers Investors Multi-node inhibition: Multi-node inhibition: overcoming the complexity overcoming the complexity of a major cancer pathway. of a major cancer pathway. PIKTOR The Challenge Clinical Results Pipeline Publications Single node inhibitors of the PAM pathway are approved for the treatment of certain cancers, but their class toxicities have constrained adoption. PIKTOR takes a different approach: by targeting multiple nodes simultaneously, each component is designed to be administered at substantially
S-3/A 1 d133316ds3a.htm S-3/A S-3/A Table of Contents As filed with the Securities and Exchange Commission on June 2, 2026 Registration No. 333-295362 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO. 1 to FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Sensei Biotherapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 83-1863385 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) … aq Stock Market LLC (“Nasdaq”) listing rules (the “Conversion Proposal”) and of a certificate of amendment to our amended and restated certificate of incorporation to increase the number of authorized shares of Common Stock from 12,500,000 to 300,000,000 (the “Authorized Share Proposal” and, together with the Conversion Proposal, the “Required Company Stockholder Matters”) and certain beneficial ownership limitations set by each … Stockholder Matters, the Annual Meeting (as defined below), the Nasdaq Listing Application (as defined below), the expected Company name and ticker if the Required Company Stockholder Matters and the Nasdaq Listing Application are approved, our ability to achieve the expected benefits or opportunities with respect to the Acquisition, our future results of operations and financial position, business strategy, our expectations that our cash and cash equivalents, together with … , together with the proceeds from the 2026 Private Placement, will enable us to fund our operating expenses and capital expenditure requirements through topline data readouts from both our ongoing Phase 2 trial of PIKTOR in advanced endometrial cancer (Study FTH-PIK-201) and our Phase 1b trial of PIKTOR in HR+/HER2- advanced breast cancer (Study FTH-PIK-101), our preclinical and clinical development activities, the potential therapeutic benefits and economic value of our prod … holder at any time following the approval by Nasdaq of a Nasdaq initial listing application filed in accordance with Nasdaq listing rule 5110(a) (the “Nasdaq Listing Application”) and approval of the Required Company Stockholder Matters. In addition, the outstanding warrant to purchase shares of Faeth Subsidiary capital stock was conv
Park Square Places Brian Stephenson, Ph.D., C.F.A., as Chief Financial Officer at Faeth Therapeutics, Park Square Executive Search Client Login Username Password Login Who We Are Why Us Where We Excel Education & Not-for-Profit Life Sciences & Healthcare Technology News Education & Not-for-Profit Life Sciences & Healthcare Technology Insights Education & Not-for-Profit Life Sciences & Healthcare Technology Contact Us Client Login Username Password Login Who We Are Why Us Where We Excel Education & Not-for-Profit Life Sciences & Healthcare Technology News
Faeth Therapeutics About Science & Pipeline Patients Careers Investors Break through Break through the PAM barrier. the PAM barrier. Faeth Therapeutics is pioneering multi-node inhibition of the PAM (PI3K/AKT/mTOR) pathway — the most frequently altered oncogenic pathway in cancer. Our lead candidate PIKTOR is an all-oral combination that is designed to achieve deeper pathway suppression with greater tolerability by targeting multiple nodes simultaneously. ABOUT PIKTOR – Tumors reroute. PIKTOR seeks to close the exits. PIKTOR is designed to inhibit PI3K-alpha, mTORC1, and mTORC2. Three node
Faeth Therapeutics Acquired by Sensei Bio: Peoplepath's Role | peoplepath.io posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in … he development of new treatments, we’d love to hear from you. 👉 Learn more and apply: https://lnkd.in/eTRCfyeT Know someone who could be a great fit? Please share! #Hiring #PlatformEngineering #Cloud #AI #Biotech #DrugDiscovery #RareDisease Job - Healx healx.ai 6 1 Comment Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in Amber Hayes MSc 3mo Report this post 𝐌𝐋 𝐃𝐢𝐬𝐜𝐨𝐯𝐞𝐫𝐲 𝐇𝐢𝐫𝐢𝐧𝐠 𝐌𝐲𝐭𝐡𝐬 🔎 Sourcing ML talent in drug discovery is
Sensei Biotherapeutics Changes Corporate Name To Faeth Therapeutics, Ticker To FTH, Effective June 16; Appoints Anand Parikh Chairman, President And CEO; Brian Stephenson Appointed CFO, Effective June 12 Download About Us Support العربية Invest Products Pricing Academy Free Stocks Hot Trading Sahm ID My Account Log Out Sign up / Log in Open Account Open Account Home News Detail Sensei Biotherapeutics Changes Corporate Name To Faeth Therapeutics, Ticker To FTH, Effective June 16; Appoints Anand Parikh Chairman, President And CEO; Brian Stephenson Appointed CFO, Effective June 12 Benzinga News 1
Sensei Biotherapeutics details Faeth deal and cash risk | SNSE Annual Report (10-K) --> STOCK TITAN Login Sign up Login Sign up 0 HOME --> NEWS FEED Stock News Live Stock News Today Trending News AI news FDA Approvals Clinical Trials Crypto News Merger & Acquisitions Earnings Offerings IPO News Stock Splits Top News - Gainers Top News - Losers SEC FILINGS SEC Filings Live SEC Filings Today Form 4 - Insider Trading 8-K - Material Events 10-K - Annual Reports 10-Q - Quarterly Reports DEF 14A - Proxy Statements S-1 - IPO Registration S-3 - Shelf Registration STOCKS All Stock Themes AI Stocks Cryp … eding 12 months (or for such shorter period that the Registrant was required to submit such files). Yes ☒ No ☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” … which we estimate our existing cash and cash equivalents will be sufficient to fund our future operating expenses and capital expenditure requirements; • the impact of laws and regulations; • our expectations regarding the period during which we will qualify as an emerging growth company under the JOBS Act; and • our anticipated use of our existing resources and the proceeds of any offerings of our securities.   These statements involve known and unkno … ors o Gedatolisib , an IV pan-PI3K/mTOR inhibitor from Celcuity, whose New Drug Application for HR+/HER2-, PIK3CA wild-type metastatic breast cancer was accepted by the FDA in January 2026 with Priority Review and a Prescription Drug User Fee Act goal date of July 17, 2026. Gedatolisib’s clinical efficacy data is discussed in the context of MNI class validation in the breast cancer development section above. o Paxalisib , an oral brain penetrant pan-PI3K/mTOR inhibitor … d legacy patent estate included one issued U.S. patent, one pending U.S. patent application, and nine international patent applications. We also co-own five pending U.S. patent applications and five pending international patent applications. We own one U.S. non-provisional and eight international patent applications relating to composition of mat
We’re proud to announce that Faeth is... - Faeth Therapeutics Facebook Log In Faeth Therapeutics's Post Faeth Therapeutics is with Foundation for Women's Cancer . August 21, 2025 · Shared with Public We’re proud to announce that Faeth is a Community Sponsor for the Race to End Women’s Cancer hosted by the Foundation for Women's Cancer ! This inspiring event on September 14 in Washington, DC, fuels vital research, treatment advancements, and hope for women facing gynecologic cancers. At Faeth, we’re deeply committed to supporting clinical research and education that brings better
Faeth Therapeutics Appoints Dr. Stephen Hahn and Dr. Jayson Dallas to Board of Directors | Faeth Therapeutics LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in,
Stream episode Episode 238 - Oliver Maddocks From Faeth Therapeutics by Project Purple Podcast podcast | Listen online for free on SoundCloud SoundCloud JavaScript is disabled You need to enable JavaScript to use SoundCloud Show me how to enable it Episode 238 - Oliver Maddocks From Faeth Therapeutics by Project Purple Podcast published on 2023-02-16T17:31:46Z This week, we’re joined by Oliver Maddocks, Co-Founder & Head of Research at Faeth Therapeutics and Professor of Cancer Biology & Metabolism at The University of Glasgow. Oliver is an expert in cancer metabolism and a pioneer in
- YouTube Info Presse Urheberrecht Kontakt Creator Werben Entwickler Impressum Verträge hier kündigen Nutzungsbedingungen Datenschutz Richtlinien & Sicherheit Wie funktioniert YouTube? Neue Funktionen testen © 2026 Google LLC
Ep113: Lewis Cantley & Siddhar... - The Long Run with Luke Timmerman - Apple 播客 搜索 主页 新发现 排行榜 搜索 2022年5月9日 40 分钟 Ep113: Lewis Cantley & Siddhartha Mukherjee on Fighting Cancer with Food and Drugs The Long Run with Luke Timmerman 播放 Lewis Cantley and Siddhartha Mukherjee, co-founders of Faeth Therapeutics, on fighting cancer with food and drug combinations. 单集网页 信息 节目 The Long Run with Luke Timmerman 频率 半月一更 发布时间 2022年5月9日 UTC 18:12 时长 40 分钟 分级 儿童适宜 美国 (简体中文) Español (México) العربية Русский Français (France) 한국어 Português (Brazil) Tiếng Việt 繁體中文 (台灣) English (US) 选择国家或地区 非洲、中东和印度 查看全部
Faeth Therapeutics Shows Preclinical Proof-of-Concept for Drug-Diet Combination to Treat Cancer, in Peer-Reviewed Publication | Anand Parikh LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clickin
Stream Ep113: Lewis Cantley & Siddhartha Mukherjee on Fighting Cancer with Food and Drugs by The Long Run with Luke Timmerman | Listen online for free on SoundCloud SoundCloud JavaScript is disabled You need to enable JavaScript to use SoundCloud Show me how to enable it Ep113: Lewis Cantley & Siddhartha Mukherjee on Fighting Cancer with Food and Drugs by The Long Run with Luke Timmerman published on 2022-05-09T18:12:31Z Lewis Cantley and Siddhartha Mukherjee, co-founders of Faeth Therapeutics, on fighting cancer with food and drug combinations. Users who like Ep113: Lewis Cantley &
Ep113: Lewis Cantley & Siddhar… - The Long Run with Luke Timmerman - Apple Podcasts Search Home New Top Charts Search May 9, 2022 40 min Ep113: Lewis Cantley & Siddhartha Mukherjee on Fighting Cancer with Food and Drugs The Long Run with Luke Timmerman Play Lewis Cantley and Siddhartha Mukherjee, co-founders of Faeth Therapeutics, on fighting cancer with food and drug combinations. Episode Webpage Information Show The Long Run with Luke Timmerman Frequency Updated Semimonthly Published May 9, 2022 at 6:12 PM UTC Length 40 min Rating Clean United States Español (México) العربية Русский
Could food improve cancer treatment? – That Cancer Conversation podcast - Cancer Research UK - Cancer News | Cancer Research UK (CRUK) LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Cont
Precision nutrition is the fourth pillar in cancer care, says Faeth Therapeutics Vitafoods Insights is part of the Informa Markets Division of Informa PLC Informa PLC | ABOUT US | INVESTOR RELATIONS | TALENT This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726. Reports Webinars Events Programmes Subscribe Subscribe Nutrients & Supplements Related Topics Botanicals & Herbs Dietary Fibre Omega-3 & Fatty Acids P
Faeth Therapeutics raises $25M to fight cancer with precision nutrition | Jesse Landry posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or s … signed to read the biology of chronic disease directly from blood. In our first application, we aim to detect MASH, a progressive liver disease, with the accuracy once possible only through tissue biopsy. Rohit Loomba , Hepta's chief medical and scientific adviser and director of the MASLD (metabolic dysfunction‑associated steatotic liver disease) Research Center at the UC San Diego , said: "This test provides a novel way to address a major unmet clinical need to have a liqui … s joined as new investors, while LYZZ CAPITAL Advisors and Lincoln Park Capital Fund doubled down as returning believers. Together, they push Onchilles' total Series A to $32M, with cumulative funding now sitting at roughly $40M. On the board, you'll find some serious horsepower: Kevin Li , Ph.D. (LYZZ), Michael Liang , Ph.D. (Invivium), and Thomas DeSouza (Kennedy Lewis), each backing a science that's equal parts elegance and precision. The data isn't hype, it's hard proof.
Faeth Therapeutics Believes in Precision Nutrition to Starve Cancer genprowebdirectory End Meta Pixel Code --> Facebook Linkedin RSS Twitter Youtube GEN Edge Featured News Multimedia Content News Insights Topics Artificial Intelligence Bioprocessing Cancer Drug Discovery Genome Editing Infectious Diseases OMICs Translational Medicine Magazine Browse Issues Subscribe Multimedia Summits Webinars GEN Live Learning Labs Podcasts Videos Resources A-Lists eBooks/Perspectives Tutorials Peer-Reviewed Journals GEN Biotechnology Re:Gen Open New Products Subscribe Get GEN Magazine Get GEN eNewsletters Se … al Sloan Kettering Cancer Center, and Siddhartha Mukherjee, MD, PhD, a Pulitzer Prize-winning oncologist, and professor at the Columbia University Irving Medical Center. (Mukherjee is the author of two best-selling books, The Emperor of All Maladies and The Gene. ) On June 30, 2022, Faeth Therapeutics announced the closing of a $47-million Series A round of private financing led by S2G Ventures, bringing total funding to $67 million. The financing proceeds will be used to adv
Faeth's Anand Parikh: "Nutrition as the fourth pillar of cancer care" - The Times Tech Podcast | Acast Follow Share Play The Times Tech Podcast Faeth's Anand Parikh: "Nutrition as the fourth pillar of cancer care" Season 1 • Friday, September 16, 2022 The Sunday Times’ tech correspondent Danny Fortson brings on Anand Parikh, co-founder and chief executive of Faeth Therapeutics, to talk about using nutrition to treat cancer (3:30), pairing it with chemotherapy (8:45), growing up in London (10:00), moving from corporate law to a startup (12:00), starting Faeth (17:1
Faeth's Anand Parikh: "Nutriti… - The Times Tech Podcast - Apple Podcasts Search Home New Top Charts Search September 16, 2022 40 min Faeth's Anand Parikh: "Nutrition as the fourth pillar of cancer care" The Times Tech Podcast Play The Sunday Times’ tech correspondent Danny Fortson brings on Anand Parikh, co-founder and chief executive of Faeth Therapeutics, to talk about using nutrition to treat cancer (3:30), pairing it with chemotherapy (8:45), growing up in London (10:00), moving from corporate law to a startup (12:00), starting Faeth (17:10), a dream team of cancer scientists (18:30
Faeth Therapeutics Appoints Stephen Hahn and Jayson Dallas to Board of Directors | FirstWord PHARMA You need to enable JavaScript to run this app. Loading...
Sensei Bio Acquires Faeth Therapeutics, Advances PIKTOR with $200M Financing | Chris Gerry posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join
Sensei Biotherapeutics buys Faeth, raises $200M | SNSE 8-K Filing --> STOCK TITAN Login Sign up Login Sign up 0 HOME --> NEWS FEED Stock News Live Stock News Today Trending News AI news FDA Approvals Clinical Trials Crypto News Merger & Acquisitions Earnings Offerings IPO News Stock Splits Top News - Gainers Top News - Losers SEC FILINGS SEC Filings Live SEC Filings Today Form 4 - Insider Trading 8-K - Material Events 10-K - Annual Reports 10-Q - Quarterly Reports DEF 14A - Proxy Statements S-1 - IPO Registration S-3 - Shelf Registration STOCKS All Stock Themes AI Stocks Crypto Stocks Oil & Ga … defined below), the Company has agreed to hold a stockholders’ meeting to submit the following matters to its stockholders for their consideration (i) the approval, in accordance with certain of the rules of the Nasdaq Stock Market, LLC (“ Nasdaq ”) of the conversion of the Series B Preferred Stock into shares of Common Stock (the “ Conversion Proposal ”), (ii) the approval of a “change of control” under Nasdaq Listing Rules 5110 … 221; under Nasdaq Listing Rules 5110 and 5635(b) (the “ Change in Control Proposal ”), (iii) amendment of the Company’s certificate of incorporation to authorize an increase of up to 300,000,000 shares of Common Stock (the “ Charter Amendment Proposal ” and, together with the Conversion Proposal and the Change in Control Proposal, the “ Company Stockholder Matters ”), (iv) to the extent deemed necessary or advisable by the Company or … ve February 17, 2026, the Company granted Mr. Parikh a sign-on equity award consisting of an option (the “ Parikh Option ”) to purchase 1,239,305 shares of Common Stock at a per-share exercise price equal to the fair market value of a share of Common Stock on the date of grant. The Parikh Option is eligible to vest, on a schedule whereby 25% of the shares of Common Stock subject to the Parikh Option will vest on the first anniversary of the date of grant … #8217;s 2021 Equity Incentive Plan, and pursuant to the terms of the applicable award agreement. Mr. Parikh has no family relationships with any of the executive officers or directors of the Company. Except as otherwise described in the Merger Agreement, there are no arrangements or understandings between Mr. Parikh and any other person
Faeth Therapeutics closes $20M seed to turn nutrition into a pillar of cancer treatment | TechCrunch –:–:–:– The first StrictlyVC of 2026 hits SF on April 30. Tickets are going fast. Register now. Founder Summit ticket savings of up to $190 end June 26. Join 1,000+ founders and VCs for all-day bootcamp. REGISTER NOW. Close TechCrunch Desktop Logo TechCrunch Mobile Logo Latest Startups Venture Apple Security AI Apps Disrupt 2026 Events Podcasts Newsletters Search Submit Site Search Toggle Mega Menu Toggle Topics Latest AI Amazon Apps Biotech & Health Climate Cloud Co … author of “ The Emperor of All Maladies” (winner of a 2011 Pulitzer Prize for General Nonfiction ) and an oncologist at Columbia University; Lewis Cantley, director of Weill Cornell’s Meyer Cancer Center and discoverer of the PI3K signaling pathway; and Karen Vousden, chief scientist of Cancer Research UK, and group leader at the Francis Crick Institute. Vousden is known for her work on the p53 tumor suppressor protein. Cantley and Vousden in particular, have been
Careers — Faeth Therapeutics About Science & Pipeline Patients Careers Investors Break through Break through with us. with us. We're building a team of exceptional scientists, clinicians, and operators who believe the next breakthrough in oncology starts with the courage to think differently. OUR VALUES – What we value Care. We care deeply about what we are doing and who we are doing it for: our patients and teammates. Create. We are changing the paradigm of oncology and that requires courage and the ability to think differently. Learn. We want to have bold ideas, fail fast and learn
Faeth Therapeutics | Biotech Careers Skip to main content Biotech Careers Contact Submit an Employer Contact Add an Employer Search Open main menu Contact Submit an Employer Contact Add an Employer Search Main navigation Careers Job Areas People Articles Videos Biotech Companies Biotech Jobs Business Areas Faeth Therapeutics Website: Faeth Therapeutics Business Area(s) Artificial Intelligence Metabolism Cancer Therapeutics Description Faeth Therapeutics is a clinical-stage biotechnology company that combines precision nutrition, AI-driven discovery, and cancer metabolism research to starve tum
Clinical Data Manager @ Faeth Therapeutics | Able Partners Job Board able join Discover exciting roles across our portfolio companies body mind home community Search jobs Explore companies Join talent network Talent My job alerts Clinical Data Manager Faeth Therapeutics This job is no longer accepting applications See open jobs at Faeth Therapeutics . See open jobs similar to " Clinical Data Manager " Able Partners . Data Science United States Posted 6+ months ago Faeth Therapeutics is a biotech start-up founded in 2019 by an international group of world-leading cancer research scien … ture Faeth was founded in 2019 by Siddhartha Mukherjee, oncologist and Pulitzer Prize winning author, Karen Vousden, Chief Scientist of CRUK & Lew Cantley, Director of the Meyer Cancer Center at Weill Cornell among others. Faeth’s investors include Khosla Ventures, Future Ventures, Digitalis and many more. We are an equal opportunity employer and we value diversity at our company. We do not discriminate on the basis of race, religion, color, national origin, gender, sexua
Faeth Therapeutics | KdT Ventures Job Board KdT Ventures Join Our Companies Discover available job opportunities within our portfolio • jobs · • companies Search jobs Explore companies Join talent network Talent My job alerts Faeth Therapeutics faeththerapeutics.com Locations San Francisco, CA, USA · Kearny, NJ, USA industry Biotechnology · Biotechnology Research · Health Care · Medical · Therapeutics Size 11 - 50 employees Stage Other founded in 2019 Socials LinkedIn Crunchbase Twitter Facebook About Faeth Therapeutics is a data-driven, evidence-based company that specializes in mechanistic u
Jobs at Faeth Therapeutics Current openings at Faeth Search 5 jobs Clinical Operations Job Clinical Data Manager San Francisco, CA Senior Clinical Scientist San Francisco, CA Senior Medical Director San Francisco, CA Food Ops & Dietetics Job Kitchen Manager/Executive Chef Denver, CO G&A Job HR Lead San Francisco, CA Powered by Greenhouse
Careers — Faeth Therapeutics About Science & Pipeline Patients Careers Investors Break through Break through with us. with us. We're building a team of exceptional scientists, clinicians, and operators who believe the next breakthrough in oncology starts with the courage to think differently. OUR VALUES – What we value Care. We care deeply about what we are doing and who we are doing it for: our patients and teammates. Create. We are changing the paradigm of oncology and that requires courage and the ability to think differently. Learn. We want to have bold ideas, fail fast and learn
Sensei Biotherapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene T … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Sensei Biotherapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update March 30, 2026 | 7 min read Twitter LinkedIn Facebook Email Print Faeth acquisition adds PIKTOR, an all-oral combination product candidate targeting multiple nodes of the PI3K/AKT/mTOR pathway $200 million privat … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Sensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Ge … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Sensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update May 17, 2026 | 8 min read Twitter LinkedIn Facebook Email Print First patient dosed in Phase 1b/2 trial of PIKTOR in HR+/HER2- advanced breast cancer Topline Phase 2 data in patients with advanced endometrial … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Sensei Biotherapeutics Announces Acquisition of Faeth Therapeutics and $200 Million Concurrent Private Placement - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Tre … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Sensei Biotherapeutics Announces Acquisition of Faeth Therapeutics and $200 Million Concurrent Private Placement February 18, 2026 | 11 min read Twitter LinkedIn Facebook Email Print Acquisition of Faeth and concurrent $200 million private investment positions the combined company to advance its pipeline … PhD (discoverer of the PI3K pathway), Siddhartha Mukherjee, MD, DPhil (Pulitzer Prize–winning physician-scientist), Karen Vousden, PhD, Scott Lowe, PhD, and Greg Hannon, PhD. About PIKTOR PIKTOR is a proprietary investigational all-oral combination of serabelisib and sapanisertib that inhibits multiple nodes of the PI3K/AKT/mTOR pathway, including PI3K-alpha and dual mTORC1/2. In a completed Phase 1b trial, PIKTOR plus paclitaxel demonstrated an overall response rate of 47% i … sp; 2 min read · Nick Paul Taylor Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst Mergers & acquisitions Serapha takes reverse merger route to Nasdaq with $230M and gene editor from China June 24, 2026 · 2 min read · Tristan Manalac Drug pricing BIO 2026: Biopharma dealmakers seek to protect ‘premium pri … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
10-K 0001829802 --12-31 P1Y 0.020833 FY one year one year false 0001829802 snse:TwoThousandAndEighteenBridgeNotesMember 2019-12-31 0001829802 us-gaap:ResearchMember 2021-01-01 2021-12-31 0001829802 snse:ConvertiblePreferredStockSeriesBBMember 2020-12-31 0001829802 us-gaap:OverAllotmentOptionMember us-gaap:CommonStockMember 2021-02-03 2021-02-03 0001829802 us-gaap:WarrantMember snse:EquityAndDebtFundraisingEventsMember 2019-01-01 2019-12-31 0001829802 us-gaap:WarrantMember snse:EquityAndDebtFundraisingEventsMember 2020-01-01 2020-12-31 0001829802 snse:TwoThousandTwentyOneEmployeeStockPurchasePl … eding 12 months (or for such shorter period that the Registrant was required to submit such files). Yes ☒ No ☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth compan … which we estimate our existing cash and cash equivalents will be sufficient to fund our future operating expenses and capital expenditure requirements;     • the impact of laws and regulations; • our expectations regarding the period during which we will qualify as an emerging growth company under the JOBS Act; and • our anticipated use of our existing resources and the proceeds of any offerings pursuant to this Report.   These statements … toxicology data from our single dose non-human primate studies in mid-2022 and submit an IND in the first half of 2023. SNS-102: Monoclonal Antibody Targeting VSIG4 VSIG-4 (V-set and Ig domain-containing 4; also known as CRIg, or complement receptor of the Ig superfamily) is a B7-related family member, which is highly expressed on macrophages, including TAMs. VSIG-4 has been shown to be a potent inhibitor of T cell proliferation. Furthermore, VSIG-4 inhibits proinflammatory … tent term is 20 years from the earliest date of filing a non-provisional patent application. In the United States, a patent’s term may be lengthened by patent term adjustment, which compensates a patentee for administrative delays by the U.S. Patent and Trademark Office, or USPTO, in examining and granting a patent, or may be shortened if
Siddhartha Mukherjee and Anand Parikh On A New Way To Fight Cancer About Entrepreneurial Resources Team Portfolio Search Menu Societal Innovation Siddhartha Mukherjee and Anand Parikh On A New Way To Fight Cancer Anand Parikh Sid Mukherjee September 21, 2022 More than 50 years ago, President Nixon announced a moonshot to cure cancer. But the cure never came. More than half a million Americans still die from cancer every single year. Pulitzer-Prize-winning author and cancer physician Siddhartha Mukherjee says that, in some ways, the scientific community has failed - and it must embrace new appr … cancer, and an assistant professor of medicine, at Columbia. He won a Pulitzer Prize, for his book on cancer, The Emperor of All Maladies. Siddhartha Mukherjee : When The Cancer Moonshot was launched, we understood very little about cancer. This was a time, when there was a big debate about, "What cancer is, as a disease? Is it a viral disease? Is it a genetic disease? Is it a combination?" Kara Miller : "Treatments were also perplexing, to doctors and researc … herapeutics. Sid Mukherjee is also a co-founder of Faeth, as well as a Pulitzer Prize winning author, a physician, and an assistant professor of medicine, at Columbia. Thanks so much, to both of you. Siddhartha Mukherjee : Pleasure. My pleasure. Anand Parikh : Thank you, Kara. Kara Miller : And thanks, as always, to you, for joining us. Coming up next week,Speaker 6:We find that for successful venture capitalists, they, actually, aren't very swayed by charisma and passio
Floor Talk with Faeth Therapeutics CEO + Co-Founder Anand Parikh | Anand Parikh LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User A
Faeth Therapeutics About Science & Pipeline Patients Careers Investors Break through Break through the PAM barrier. the PAM barrier. Faeth Therapeutics is pioneering multi-node inhibition of the PAM (PI3K/AKT/mTOR) pathway — the most frequently altered oncogenic pathway in cancer. Our lead candidate PIKTOR is an all-oral combination that is designed to achieve deeper pathway suppression with greater tolerability by targeting multiple nodes simultaneously. ABOUT PIKTOR – Tumors reroute. PIKTOR seeks to close the exits. PIKTOR is designed to inhibit PI3K-alpha, mTORC1, and mTORC2. Three node
Sensei Biotherapeutics updates 10-K business overview | SNSE Annual Report (10-K) --> STOCK TITAN Login Sign up Login Sign up 0 HOME --> NEWS FEED Stock News Live Stock News Today Trending News AI news FDA Approvals Clinical Trials Crypto News Merger & Acquisitions Earnings Offerings IPO News Stock Splits Top News - Gainers Top News - Losers SEC FILINGS SEC Filings Live SEC Filings Today Form 4 - Insider Trading 8-K - Material Events 10-K - Annual Reports 10-Q - Quarterly Reports DEF 14A - Proxy Statements S-1 - IPO Registration S-3 - Shelf Registration STOCKS All Stock Themes AI Stocks Crypto … eding 12 months (or for such shorter period that the Registrant was required to submit such files).  YES  ☒ NO ☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “eme … #160; Gedatolisib , an IV pan-PI3K/mTOR inhibitor from Celcuity, whose New Drug Application for HR+/HER2, PIK3CA wild-type metastatic breast cancer was accepted by the FDA in January 2026 with Priority Review and a Prescription Drug User Fee Act goal date of July 17, 2026. Gedatolisib’s clinical efficacy data is discussed in the context of MNI class validation in the breast cancer development section above.     •   Paxalisib , an oral brain pen … d legacy patent estate included one issued U.S. patent, one pending U.S. patent application, and nine international patent applications. We also co-own five pending U.S. patent applications and five pending international patent applications. We own one U.S. non-provisional and eight international patent applications relating to composition of matter of our solnerstotug product candidate and method claims including use in combination with immune checkpoint protein inhibitors. … eement, we are granted an exclusive, royalty-bearing license, with the right to grant sublicenses, under certain patents and know-how controlled by Takeda to research, develop, make, have made, import, export, use, have used, sell, have sold, offer for sale, or otherwise dispose of and commercialize serabelisib and certain back-up compounds, and
#asco2026 #oncologyresearch #cancerresearch #womenscancer | Faeth Therapeutics LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Ag
Faeth Therapeutics - Executive Bio, Top Executies, and Transitions - Equilar ExecAtlas Request a Demo Win Deals Through Your Network Transform relationships with clients, colleagues, and partners into actionable insights. Search for an Executive Trusted by Trusted by Featured Organization Faeth Therapeutics faeththerapeutics.com Company Details Description Faeth Therapeutics is a clinical-stage biotechnology company at the forefront of oncology with a robust clinical and preclinical pipeline powered by its AI-driven MetabOS discovery platform. Faeth’s lead program, PIKTOR, has shown outstandin … imulation of PI3K is impaired. I want to thank the founders of the Breakthrough Prize in Life Sciences for establishing this incredible prize to highlight the importance and excitement of scientific research. I also want to thank the numerous brilliant graduate students and postdocs in my lab over the years who have tolerated my wild ideas, usually proving them wrong, but in the process of doing so, occasionally finding new and exciting insights into biology. I especially wan … ce. Dr. Lowe’s work has been recognized by the Sydney Kimmel Foundation Scholar Award, a Rita Allen Foundation Scholar Award, the AACR Outstanding Investigator Award and the Paul Marks Prize for Cancer Research, among others. He has been inducted as a Fellow in the American Academy of Arts and Sciences. Previously, Dr. Lowe was a member of the faculty at Cold Spring Harbor Laboratory. Dr. Lowe received his PhD at the Massachusetts Institute of Technology and his BS from the U … imulation of PI3K is impaired. I want to thank the founders of the Breakthrough Prize in Life Sciences for establishing this incredible prize to highlight the importance and excitement of scientific research. I also want to thank the numerous brilliant graduate students and postdocs in my lab over the years who have tolerated my wild ideas, usually proving them wrong, but in the process of doing so, occasionally finding new and exciting insights into biology. I especially wan … ce. Dr. Lowe’s work has been recognized by the Sydney Kimmel Foundation Scholar Award, a Rita Allen Foundation Scholar Award, the AACR Outstanding Investigator Award and the Paul Marks Prize for Cancer Research, among others. He has been inducted as a Fellow in the American Academy of Arts and Sciences. Previously, Dr. Lowe was a member of the fa
Faeth Therapeutics Acquired by Sensei Bio, Advancing PIKTOR in Endometrial Cancer Trials | Faeth Therapeutics posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clickin … r ending December 31, 2025, with a cash position of $107.6 million, expected to fund operations into the second half of 2028. The trial aims to provide initial proof-of-concept data for BBI-940, which is designed to disrupt extrachromosomal DNA (ecDNA) segregation in oncogene amplified cancers. Additionally, Boundless announced the cessation of enrollment in the Phase 1/2 POTENTIATE trial to prioritize the BBI-940 program. The company reported a net loss of $58.2 million for
Presented at AAIC 2025 in Toronto, shared work on recombinant antibodies for diagnostics | Aviva Systems Biology posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clic … his post Reprogramming autoimmunity In a compelling follow-up to his 2025 Nobel Prize, Shimon Sakaguchi and colleagues have published two papers demonstrating the directed conversion of autoreactive T cells into regulatory T cells (Tregs) via non-genomic modulation. Using a small molecule to upregulate Foxp3, the master transcription factor for Treg lineage commitment and simultaneously inhibiting CD28 signaling, the team achieved stable Treg phenotypes in both murine and hum … Dr. Chiou-Hwa Yuh (National Health Research Institutes, Taiwan) 🗓️ Submission Deadline: 31 August 2026 🔗 Submit your work and help shape the future of AI-guided precision dosing in oncology: https://lnkd.in/eZwrk_X4 #TranslationalOncology #CombinationTherapy #DoseOptimization #PhenotypicResponseSurface #Biomarkers #MultiOmics #PrecisionOncology #OncologyResearch #TechSciencePress 1 Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in Faeth Therapeu
Faeth Therapeutics to Participate in Upcoming Jefferies Investor Conference - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opin … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Lone Star Bio Faeth Therapeutics to Participate in Upcoming Jefferies Investor Conference May 30, 2024 | 2 min read Twitter LinkedIn Facebook Email Print Faeth Therapeutics announced today that Anand Parikh, Chief Executive Officer (CEO), will participate in one-on-one investor meetings at the upcoming Jefferies Global … bsp; 2 min read · Tristan Manalac Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst China BIO 2026: US needs to dodge China’s ‘inescapable dependencies’ to protect biotech June 24, 2026 · 2 min read · Annalee Armstrong BioSpace at BIO to find out" href="https://www.biospace.com/drug-development/can-adcs-be-kin … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
We had a great time at the inaugural AI Bio Summit at the NYSE last week. An inspiring group of founders, investors, and industry leaders gathered to reflect on the role of AI in biotechnology over… | Faeth Therapeutics LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choice
- YouTube Info Presse Urheberrecht Kontakt Creator Werben Entwickler Impressum Verträge hier kündigen Nutzungsbedingungen Datenschutz Richtlinien & Sicherheit Wie funktioniert YouTube? Neue Funktionen testen © 2026 Google LLC
Faeth Therapeutics About Science & Pipeline Patients Careers Investors Break through Break through the PAM barrier. the PAM barrier. Faeth Therapeutics is pioneering multi-node inhibition of the PAM (PI3K/AKT/mTOR) pathway — the most frequently altered oncogenic pathway in cancer. Our lead candidate PIKTOR is an all-oral combination that is designed to achieve deeper pathway suppression with greater tolerability by targeting multiple nodes simultaneously. ABOUT PIKTOR – Tumors reroute. PIKTOR seeks to close the exits. PIKTOR is designed to inhibit PI3K-alpha, mTORC1, and mTORC2. Three node
LongeVC joins $11.8M financing round in Valink Therapeutics | Garri Zmudze posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you … ibody-drug conjugate space! 🚀 The financing is led by European venture capital fund redalpine, and we joined the round alongside Oxford Science Enterprises, and previous investors including RV Invest, p53 Invest, and Hoxton Ventures. 🔬 Speaking about science concept, Valink is advancing a pipeline of next-generation bispecific antibody-drug conjugates (bsADCs) to address limitations of traditional ADCs. Their proprietary V-gate™ discovery platform integrates novel targeting … ge Innovation Capital , Sanofi Ventures and the University of Cambridge Venture Fund. T-Therapeutics Ltd will use the additional proceeds to drive its pipeline of first-in-class TCR-CD3 bispecifics across oncology and autoimmune diseases towards the clinic, including the further exploration of new therapeutic strategies such as T cell subset depletion. T-Therapeutics’ lead asset in oncology exploits a pan-tumour driver target, applicable across multiple different solid tumour … s, and Cantos, as well as new investors B Capital Group, Avicella, and THO Seed Fund. The post Faeth Therapeutics: $25 Million Raised To Advance PIKTOR Phase 2 Trial Following 80% Response Rate In Endometrial Cancer appeared first on Pulse 2.0. Faeth Therapeutics: $25 Million Raised To Advance PIKTOR Phase 2 Trial Following 80% Response Rate In Endometrial Cancer https://pulse2.com Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in Life Sciences VCL … res , KdT Ventures , Cantos , B Capital Group , Avicella Capital , and THO Seed Fund. The Austin-based company develops therapies targeting tumor metabolism through multi-node inhibition of the PI3K/AKT/mTOR pathway. Faeth also presented results from two cancer trials (ovarian cancer & endometrial cancer) at the European Society for Medical O
EX-10.4 7 d112826dex104.htm EX-10.4 EX-10.4 Exhibit 10.4 S ENSEI B IOTHERAPEUTICS , I NC . I NDUCEMENT G RANT O UTSIDE OF 2021 E QUITY I NCENTIVE P LAN S TOCK O PTION G RANT N OTICE Sensei Biotherapeutics, Inc. (the “ Company ”), outside of, but subject to the terms of, its 2021 Equity Incentive Plan (the “ Plan ”), has granted to you (“ Optionholder ”) an option to purchase the number of shares of the Common Stock set forth below (the “ Option ”). This option is granted in compliance with Nasdaq Listing Rule 5635(c)(4), as a material inducement … plicable. Optionholder: Date of Grant: Vesting Commencement Date: Number of Shares of Common Stock Subject to Option:  Exercise Price (Per Share): Total Exercise Price: Expiration Date: Typ … Expiration Date: Type of Grant:   Nonstatutory Stock Option Exercise and Vesting Schedule : Subject to the Optionholder’s Continuous Service through each applicable vesting date, the Option will vest as follows: Optionholder Acknowledgements: By your signature below or by electronic acceptance or authentication in a form authorized by the Company, you understand and agree that: •   … e that: • The Option is governed by this Stock Option Grant Notice, and the provisions of the Plan and the Stock Option Agreement and the Notice of Exercise, all of which are made a part of this document. Unless otherwise provided in the Plan, this Grant Notice and the Stock Option Agreement (together, the “ Option Agreement ”) may not be modified, amended or revised except in a writing signed by you and a duly authorized officer of the C … officer of the Company. • You consent to receive this Grant Notice, the Stock Option Agreement, the Plan, the Prospectus and any other Plan-related documents by electronic delivery and to participate in the Plan through an on-line or electronic system established and maintained by the Company or another third party desig
Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 4, 2026 - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell a … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 4, 2026 June 5, 2026 | 1 min read Twitter LinkedIn Facebook Email Print BOSTON--(BUSINESS WIRE)--Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today announced that, effective on June 1, 2026, the Compensation Comm … 1, 2026, and will vest, with respect to 25% of the shares subject to each such award, on the first anniversary of the applicable employee’s start date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter, in each case subject to such employee’s continued service with Sensei through each such vesting date. About Sensei Biotherapeutics Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) is a clinical-stage biotechnology company focused on the di … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin